



(51) International Patent Classification:

C07C 233/56 (2006.01) A61P 13/12 (2006.01)
A61K 31/192 (2006.01) A61P 9/12 (2006.01)
A61P 9/00 (2006.01) A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2016/017315

(22) International Filing Date:

10 February 2016 (10.02.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/114,705 11 February 2015 (11.02.2015) US

(71) Applicant: THERAVANCE BIOPHARMA R&D IP, LLC [US/US]; 901 Gateway Boulevard, South San Francisco, California 94080 (US).

(72) Inventors: HUGHES, Adam D.; 2029 Touraine Lane, Half Moon Bay, California 94019 (US). FENSTER, Erik; 535 Redwood Avenue, San Bruno, California 94066 (US). FLEURY, Melissa; 47D Joy Avenue, Brisbane, California 94005 (US). BEAUSOLEIL, Anne-Marie; 1210 S. Claremont Street, San Mateo, California 94402 (US). THALLADI, Venkat R.; 888 Foster City Boulevard, Apt. E3, Foster City, California 94404 (US). NZEREM, Jerry; 29 Woods Circle, South San Francisco, California 94080 (US). RAPTA, Miroslav; 1240 Highland Court, San Carlos, California 94070 (US).

(74) Agents: HAGENAH, Jeffrey A. et al.; Theravance Biopharma US, INC., 901 Gateway Boulevard, South San Francisco, California 94080 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: (2S, 4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-2-ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR



(57) Abstract: In one aspect, the invention relates to a compound of the structure: (1), or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.